Austedo XR is a medication for treating chorea associated with Huntington's disease and tardive dyskinesia [1]. Austedo XR is an extended-release formulation of deutetrabenazine [2].
What is Austedo XR prescribed for?
Austedo XR is indicated for the treatment of chorea, a movement disorder characterized by involuntary, irregular, jerky movements, that can occur in patients with Huntington's disease. It is also used to manage tardive dyskinesia, another condition involving involuntary muscle movements, often a side effect of certain psychiatric medications [1].
How does Austedo XR work?
Austedo XR contains deutetrabenazine, which is a reversible inhibitor of vesicular monoamine transporter type 2 (VMAT2) [2]. VMAT2 is responsible for transporting monoamines like dopamine from the cytoplasm into synaptic vesicles. By inhibiting VMAT2, deutetrabenazine reduces the amount of dopamine available for release into the synapse, thereby helping to control involuntary movements [3]. Deuteration of tetrabenazine, the active molecule in Austedo XR, leads to slower metabolism, potentially allowing for less frequent dosing and a more stable plasma concentration [4].
When does Austedo XR patent protection end?
Information regarding specific patent expiration dates for Austedo XR is not readily available in the provided context. Drug patent information, including expiration dates and any associated litigation, can typically be found through resources that track pharmaceutical patents [5].
What are the side effects of Austedo XR?
Common side effects associated with Austedo XR include upper respiratory tract infection, insomnia, and fatigue [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is Austedo XR different from other treatments for Huntington's disease or tardive dyskinesia?
Austedo XR's distinctiveness lies in its formulation as an extended-release deutetrabenazine. This formulation aims to provide a more consistent level of the drug in the body over time compared to immediate-release versions, potentially allowing for less frequent dosing [4]. Other treatments for chorea and tardive dyskinesia may involve different mechanisms of action or drug classes.
Can generic versions of Austedo XR be available?
The availability of generic versions of Austedo XR is dependent on patent expirations and any legal challenges to those patents. Once patent protection is no longer in effect, or if patents are successfully challenged, generic manufacturers may be able to produce and market their own versions of the drug [5].
Who manufactures Austedo XR?
Austedo XR is manufactured by Teva Pharmaceuticals [6].
What clinical data supports Austedo XR's efficacy?
Clinical studies have demonstrated the efficacy of Austedo XR in reducing chorea severity in patients with Huntington's disease and in managing tardive dyskinesia [1]. These studies typically assess changes in specific rating scales for involuntary movements.
What are the risks associated with taking Austedo XR?
Austedo XR carries a boxed warning for depression and suicidal ideation and behavior in patients with Huntington's disease. Patients taking Austedo XR should be monitored for these symptoms. Other risks include somnolence and parkinsonism. It is crucial for patients to be aware of these potential risks and to discuss them thoroughly with their doctor [1].
Are there alternatives to Austedo XR?
For Huntington's disease chorea, other VMAT2 inhibitors like Xenazine (tetrabenazine) have been used. For tardive dyskinesia, other treatment options may include different classes of medications or dose adjustments of the offending agent [3, 7]. The choice of treatment depends on individual patient factors, disease severity, and tolerability of side effects.
What is the typical dosage and pricing for Austedo XR?
Dosage and pricing for Austedo XR vary based on individual patient needs, insurance coverage, and pharmacy. Information on specific pricing and dosage regimens should be obtained from healthcare providers or pharmaceutical assistance programs.
Sources:
[1] https://www.drugs.com/austedo-xr.html
[2] https://www.rxlist.com/austedo-xr-drug.htm
[3] https://www.drugpatentwatch.com/drug/austedeo-xr
[4] https://www.neurologyadvisor.com/home/news/deutetrabenazine-austedo-xr-for-huntingtons-disease-chorea/
[5] https://drugpatentwatch.com/
[6] https://www.fiercepharma.com/pharma/teva-s-new-drug-austedo-xr-gets-fda-nod-huntingtons-disease
[7] https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/diagnosis-treatment/drc-20356113